Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658333 · ClinicalTrials.gov registry record · Phase 4
A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00658333 is a Phase 4 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT00658333, a Phase 4 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
To determine if conversion to enteric coated MPA allows an escalated dose of mycophenolic acid (MPA) to be tolerated in patients experiencing gastrointestinal (GI) symptoms
Interventions
- DRUG Mycophenolate Mofetil (MMF)
- DRUG Enteric-coated Mycophenolate Acid (EC-MPA)
- DRUG Placebo MMF
- DRUG Placebo EC-MPA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658333
The ClinicalTrials.gov registry entry for NCT00658333 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mycophenolate Mofetil (MMF) is the first listed.
NCT00658333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658333 about?
NCT00658333 is a clinical study titled "A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms". To determine if conversion to enteric coated MPA allows an escalated dose of mycophenolic acid (MPA) to be tolerated in patients experiencing gastrointestinal (GI) symptoms
What is the current status of trial NCT00658333?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2008-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00658333?
The interventions under investigation include: Mycophenolate Mofetil (MMF) (DRUG), Enteric-coated Mycophenolate Acid (EC-MPA) (DRUG), Placebo MMF (DRUG), Placebo EC-MPA (DRUG).
Who is sponsoring clinical trial NCT00658333?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.